Intec Pharma Ltd (NTEC) Given Consensus Rating of “Buy” by Analysts

Intec Pharma Ltd (NASDAQ:NTEC) has received an average recommendation of “Buy” from the eight research firms that are covering the stock, MarketBeat reports. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1-year price objective among analysts that have covered the stock in the last year is $11.60.

A number of equities analysts have recently commented on the stock. Zacks Investment Research upgraded shares of Intec Pharma from a “sell” rating to a “hold” rating in a research report on Tuesday, February 12th. BidaskClub lowered shares of Intec Pharma from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, March 6th. LADENBURG THALM/SH SH reiterated a “buy” rating on shares of Intec Pharma in a research report on Wednesday, May 1st. Maxim Group reiterated a “buy” rating and set a $12.00 target price on shares of Intec Pharma in a research report on Tuesday, February 19th. Finally, HC Wainwright set a $16.00 target price on shares of Intec Pharma and gave the company a “buy” rating in a research report on Tuesday, May 28th.

NTEC stock opened at $4.94 on Friday. Intec Pharma has a 12 month low of $3.55 and a 12 month high of $9.25. The company has a market capitalization of $160.87 million, a PE ratio of -3.53 and a beta of 0.48.

Intec Pharma (NASDAQ:NTEC) last released its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($0.32) EPS for the quarter, beating analysts’ consensus estimates of ($0.37) by $0.05. On average, analysts predict that Intec Pharma will post -1.05 EPS for the current fiscal year.

Institutional investors have recently made changes to their positions in the business. Essex Investment Management Co. LLC bought a new stake in Intec Pharma during the fourth quarter valued at approximately $2,972,000. Menta Capital LLC bought a new stake in Intec Pharma during the first quarter valued at approximately $248,000. PRW Wealth Management LLC bought a new stake in Intec Pharma during the fourth quarter valued at approximately $29,000. BlackRock Inc. bought a new stake in Intec Pharma during the fourth quarter valued at approximately $67,000. Finally, Sigma Planning Corp bought a new stake in shares of Intec Pharma in the 1st quarter worth approximately $183,000. Institutional investors and hedge funds own 33.81% of the company’s stock.

Intec Pharma Company Profile

Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. Its Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism.

Featured Story: Why is momentum important to successful trading?

Analyst Recommendations for Intec Pharma (NASDAQ:NTEC)

Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with MarketBeat.com's FREE daily email newsletter.